ProMetic Life Sciences Inc.
TSX : PLI

ProMetic Life Sciences Inc.

May 29, 2006 13:44 ET

ProMetic Appoints New General Counsel and Corporate Secretary

MONTREAL, CANADA--(CCNMatthews - May 29, 2006) - ProMetic Life Sciences Inc. (TSX:PLI) announced today a change at the General Counsel and Corporate Secretary level. Ms Genevieve Lavertu leaves the Company to pursue her legal practice in Toronto and is being replaced by Mr. Mark Bandrauk.

"We greatly thank Genevieve Lavertu for her valuable contribution and we wish her success in her future endeavors" said Pierre Laurin, Chairman and CEO of ProMetic. "I am pleased to welcome Mark Bandrauk to the management team. His skills will be invaluable in many ways including, the negotiations of key commercial agreements and the financing of our technologies", he added.

Mark has more than ten years experience and joins ProMetic from Desjardins Securities where he was Senior Counsel and led commercial and corporate projects for the last two years.

Mark's previous work assignments include licensing matters in the telecommunications industry for VoiceAge, Avanex Corporation and Nortel Networks. At Nortel Networks, he served as senior transaction specialist providing legal and business-oriented support to various Nortel units, as well as negotiating and drafting major software licenses, joint technology developments, and sales and OEM agreements.

Before joining Nortel, Mark was legal counsel for Abitibi-Consolidated Inc. of Montreal and a junior partner, corporate and commercial law, with the firm of Demers & Associates of Sherbrooke.

Mark holds a law degree from the Universite de Sherbrooke, a master's of business administration from McGill University in Montreal and a diploma in international business studies from Universita Commerciale L. Bocconi in Milan, Italy.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ enabling technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of inflammation and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D and manufacturing facilities in the UK and the Isle of Man and business development activities in the US, Europe, Asia and countries in the Middle East and North Africa. Additional information is available on the Company's website at www.prometic.com.

Contact Information